Trial reportJournal of neuro-oncology2013
Prospective evaluation of health-related quality of life in patients with glioblastoma multiforme treated on a phase II trial of hypofractionated IMRT with temozolomide.
Trial report in Journal of neuro-oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 4 syntheses or guidelines pooled it, 39 citations in OpenAlex.
- Sleep disorders associated with cranial radiation-A systematic review.Neuro-oncology · 2025Pooled it
- External beam radiation dose escalation for high grade glioma.The Cochrane database of systematic reviews · 2020Pooled it
- Efficacy and Safety of Hypofractionated Radiotherapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2019Pooled it
- Sleep disturbance of adults with a brain tumor and their family caregivers: a systematic review.Neuro-oncology · 2017Pooled it
- Health-related quality of life, cognitive screening, and functional status in a randomized phase III trial (EF-14) of tumor treating fields with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma.Journal of neuro-oncology · 2017Trial
- Phase 1/2 Trial of 5-Fraction Stereotactic Radiosurgery With 5-mm Margins With Concurrent and Adjuvant Temozolomide in Newly Diagnosed Supratentorial Glioblastoma: Health-Related Quality of Life Results.International journal of radiation oncology, biology, physics · 2017Trial
- Single-dose radiotherapy is more effective than fractionation when combined with anti-PD-1 immunotherapy in glioblastoma.Scientific reports · 2025Article
- Sulforaphane induces cell morphology change and cell apoptosis by activating endoplasmic reticulum stress in glioblastoma.BMC cancer · 2025Article
- Sleep disturbances in brain tumors: a narrative review.Frontiers in oncology · 2025Review
- CDK7 and CDK9 inhibition interferes with transcription, translation, and stemness, and induces cytotoxicity in GBM irrespective of temozolomide sensitivity.Neuro-oncology · 2024Article
- Quality of life following concurrent temozolomide-based chemoradiation therapy or observation in low-grade glioma.Journal of neuro-oncology · 2022Article
- Psychometric evaluation of an item bank for computerized adaptive testing of the EORTC QLQ-C30 cognitive functioning dimension in cancer patients.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2017Article
- Development of an item bank for computerized adaptive testing of self-reported cognitive difficulty in cancer patients.Neuro-oncology practice · 2017Article
- New Hypofractionation Radiation Strategies for Glioblastoma.Current oncology reports · 2017Review
- Phenotypic and molecular characteristics associated with various domains of quality of life in oncology patients and their family caregivers.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2016Article
- Toward a noncytotoxic glioblastoma therapy: blocking MCP-1 with the MTZ Regimen.OncoTargets and therapy · 2016Review
- Hypofractionated chemoradiotherapy with temozolomide as a treatment option for glioblastoma patients with poor prognostic features.International journal of clinical oncology · 2015Article
- Health-related quality of life in high-grade glioma patients.Chinese journal of cancer · 2014Review
- CT perfusion imaging as an early biomarker of differential response to stereotactic radiosurgery in C6 rat gliomas.PloS one · 2014Article
- Therapeutic approach beyond conventional temozolomide for newly diagnosed glioblastoma: Review of the present evidence and future direction.Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric OncologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To report health-related quality of life (HRQOL) in glioblastoma (GBM) patients treated on a phase II trial of hypofractionated intensity-modulated radiotherapy (hypo-IMRT) with temozolomide (TMZ). GBM patients received postoperative hypo-IMRT to 60 Gy in 10 fractions with TMZ. HRQOL was assessed using the EORTC quality of life questionnaire core-30 and the EORTC brain cancer module, performed at baseline, RT completion, 1 mo post-RT, and every 3 mos thereafter. Changes from baseline were calculated for each specific HRQOL scale. A ≥ 10 point change in any HRQOL scale from the mean baseline score was significant. 24 patients were treated. Compliance with HRQOL assessments at baseline, RT completion, and 1, 3, 6, 9, and 12 mos post-RT was 100, 96, 92, 79, 70, 68 and 53 %, respectively. Up to 12 mos post-RT, no significant changes were seen in global health status, physical functioning, role functioning, emotional functioning, fatigue, nausea, vision, headache or seizure. Significant improvement was seen in insomnia, future uncertainty, motor dysfunction and drowsiness. Significant worsening was observed in cognitive functioning, social functioning, appetite loss and communication deficit. 60 Gy hypo-IMRT in 6-Gy fractions with TMZ does not appear to negatively impact overall HRQOL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.